Navigation Links
Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
Date:9/10/2009

y. Evalve's minimally invasive catheter-based MitraClip(R) system, used to clip the leaflets of the mitral valve together to reduce regurgitation, is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation. The MitraClip system is an investigational device in the United States and is currently in clinical trials.

"Combining Evalve's first in class mitral valve repair technology with Abbott's global presence, commercial infrastructure and manufacturing expertise will help advance minimally invasive treatment options for the millions of patients with mitral regurgitation," said Robert Hance, senior vice president, vascular, Abbott. "We look forward to welcoming Evalve as a key part of Abbott's vascular business."

"Patients in Europe have benefited from having access to the MitraClip technology since it received CE Mark last year," said Ferolyn Powell, president and chief executive officer of Evalve, who will continue to lead the Evalve team and will report to Hance after the acquisition closes. "We look forward to becoming a part of Abbott and working together to accelerate our business and expand our global reach to patients around the world with our minimally invasive technologies."

Under the terms of the agreement, Abbott will acquire the remaining 90 percent of outstanding equity of Evalve, Inc. that it does not already own for an upfront payment of $320 million, plus a $90 million payment if certain regulatory milestones are met. The transaction does not impact Abbott's previously issued earnings-per-share guidance for 2009.

The transaction is subject to customary closing conditions, including antitrust clearances. Abbott expects the transaction to close in the fourth quarter of 2009.

About Evalve, Inc.

Founded in 1999 by The Foundry
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
4. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
5. Abbott Named One of the Top 10 Companies for Scientists
6. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
7. Abbott to Present at Barclays Global Healthcare Conference
8. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
9. Abbott Announces 11 Percent Increase in Quarterly Dividend
10. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
11. Abbott Announces Earnings Guidance for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... NEWTOWN, Pa. , June 2, 2015   ... services and technology provider, today announced that David ... has been named Executive Vice President and Chief Financial ... 8, 2015. Peters brings more than 25 ... in pharmaceutical services. "David has extensive and deep knowledge ...
(Date:6/2/2015)... , June 2, 2015  Alere Inc. ... rapid diagnostics, joined the White House Antibiotic Stewardship ... commitments to support and advance the President,s National ... commitments include a number of measurable goals and ... achieved, will help healthcare providers protect their patients ...
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
Breaking Biology Technology:BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... BIOD ) today reported financial results for the ... Quarter Operating Highlights During Biodel,s third quarter of ... 1 testing of two new ultra-rapid-acting formulations of recombinant human ... at Oregon Health and Sciences University who have initiated a ...
... Calif. and TORONTO, Aug. 4, 2011 ... developing a first-in-class anti-apoptosis therapeutic protein known as ... www.generex.com ), a biotechnology company developing a buccal ... in a Phase III trial, today are making ...
... AMSTERDAM, The Netherlands, August 4, 2011 SynCo ... of biopharmaceuticals today announced that its aseptic filling facility is ... first drug product batches for its clients after the expansion ... of the Class A zone is an important milestone in ...
Cached Biology Technology:Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 6Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 2Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 3Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 4Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 5SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Boulder, Colo., USA New GSA Bulletin articles cover wind ... on Kauai; new insights from the Petrified Forest, USA; a ... a new model for the development of Ries Crater Lake, ... large earthquakes in northern Fiordland, New Zealand; and the evolution ...
... research at the Institute of Food Research, has taken ... and drug companies worldwide. , IFR and the technology ... from the Biotechnology and Biological Sciences Research Council (BBSRC) ... and improve how well it simulates the release of ...
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
Cached Biology News:Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 2Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 3Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 4Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 5Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 6Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 7Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 8Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 9Commercial future for Model Gut 2Cell discovery could hold key to causes of inherited diseases 2
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
100 adhesive strips....
Request Info...
Biology Products: